Drug Shortages and You: Who's At Risk, What's the Fix?
Drug shortages are a complex problem with multiple causes, not least of all manufacturing issues that can affect the safety of injectable medicines like biologics.
Drug shortages are a complex problem with multiple causes, not least of all manufacturing issues that can affect the safety of injectable medicines like biologics.
John Horton | Posted 02.20.2012
Today, too many families face President Reagan's "long goodbye" -- and too many Alzheimers' victims know, even as the disease begins to rob them of their memories, of the pain their families will face.
Gary Puckrein | Posted 02.05.2012
It is crucial that the health care communities in both the public and private sector transform their data collection and testing approaches to account for the overall changing face of the American population.
John Horton | Posted 07.19.2011
What's the right length for data exclusivity? The current law says innovator drug makers have twelve years; in the European Union, it's ten; and the 2012 budget proposes seven. Who's right?
Sen. Sherrod Brown | Posted 05.25.2011
In America, a family should never be forced into bankruptcy because a child gets sick. In America, an Ohio family shouldn't be denied coverage if it r...
John Horton | Posted 05.25.2011
Biologics are an exciting new world of medicine. But the EMA's new guidelines should put patient safety first by requiring biosimilars to be held to the same safety and standards as the original drug.
John Horton | Posted 05.25.2011
As a matter of common sense, the FDA's process for biosimilars shouldn't sacrifice patient safety.
Jane Hamsher | Posted 05.25.2011
Pelosi made a choice about the lifesaving biologic drugs I took when I was in chemotherapy that will cost many fellow breast cancer survivors everything they own, and quite possibly their lives.
Jane Hamsher | Posted 05.25.2011
Thank you, Rep. Eshoo, for your commitment to having a bill that does not allow for "evergreening." Now the question becomes -- how are we going to get one?
Pat Choate | Posted 05.25.2011
The United States will only realize this potential and remain the global leader in medical innovation if we maintain a strong environment for investment in the newest wave - biopharmaceuticals, also known as biologics.
Jane Hamsher | Posted 05.25.2011
The public option has received the lion's share of attention in the health care debate, but there's an equally important issue relating to generic drugs that could mean lifesaving drugs remain too expensive for all but the wealthy.
Marcy Winograd | Posted 05.25.2011
In Congress, I will work to support affordable prices on biologics, so that victims of cancer, HIV, diabetes, Parkinsons, rheumatoid arthritis, and multiple sclerosis can afford the medicine they need to stay alive.
Hilary Kramer | Posted 05.25.2011
You know a health care bill isn't right for the American people when it carves out a legal monopoly for Big Pharma and Botox. Our Congressional leaders should be capable of more.
Kate Kelly | Posted 05.25.2011
Legislation concerning the changes for the drug approval process on a special type of medicine (biologic medicines) could provide huge savings -- a major need with health care reform.
David Mixner | Posted 11.17.2011
For nearly three decades, too many people have died and millions more are living with HIV/AIDS' painful realities. Stated simply, it is far from over.
John Horton | Posted 05.09.2012